BlossomHill director holds option on 67,620 shares

BlossomHill Therapeutics, Inc. (BLSM) reported an initial insider ownership statement for director John P. Schmid.

Rhea-AI Filing Summary

BlossomHill Therapeutics, Inc. (BLSM) reported an initial insider ownership statement for director John P. Schmid. He holds a Director Stock Option covering 67,620 shares of common stock at an exercise price of $13.59 per share, directly owned. The option is immediately exercisable and expires on May 17, 2036.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Schmid John P.

Role Director

Type	Security	Shares	Price	Value
holding	Director Stock Option (Right to Buy) F1	--	--	--

Holdings After Transaction: Director Stock Option (Right to Buy) — 67,620 contracts (Direct)

Footnotes (1)

1. F1. Immediately Exercisable.

Key Figures

Underlying option shares: 67,620 shares Exercise price: $13.59 per share Option expiration date: May 17, 2036

3 metrics

Underlying option shares 67,620 shares Director Stock Option (Right to Buy) underlying BlossomHill Therapeutics common stock

Exercise price $13.59 per share Exercise price of the Director Stock Option held by John P. Schmid

Option expiration date May 17, 2036 Expiration date of the Director Stock Option (Right to Buy)

Key Terms

Director Stock Option (Right to Buy), Common Stock, Immediately Exercisable

3 terms

Director Stock Option (Right to Buy) financial

"security_title: Director Stock Option (Right to Buy)"

Common Stock financial

"underlying_security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Immediately Exercisable financial

"Footnote: Immediately Exercisable."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 3 filing for BLSM by John P. Schmid report?

The Form 3 for BLSM reports director John P. Schmid holding a director stock option. The option covers 67,620 shares of common stock, is immediately exercisable, has a $13.59 exercise price, and expires on May 17, 2036.

How many shares are covered by John P. Schmid’s option in BLSM?

John P. Schmid’s option covers 67,620 shares of BlossomHill Therapeutics common stock. These shares are the underlying securities of a director stock option that is immediately exercisable and directly owned, with an expiration date of May 17, 2036.

What is the exercise price of John P. Schmid’s BLSM stock option?

The exercise price of John P. Schmid’s BLSM director stock option is $13.59 per share. This option relates to 67,620 underlying common shares, is reported as directly owned, is immediately exercisable, and carries an expiration date of May 17, 2036.

When does John P. Schmid’s BLSM director stock option expire?

John P. Schmid’s director stock option in BLSM expires on May 17, 2036. The option covers 67,620 shares of common stock, is immediately exercisable, has an exercise price of $13.59 per share, and is held as a direct ownership position.

Is John P. Schmid’s BLSM stock option immediately exercisable?

Yes, the filing notes the option is Immediately Exercisable. This director stock option covers 67,620 shares of BlossomHill Therapeutics common stock at an exercise price of $13.59 per share and is reported as being held with direct ownership, expiring in 2036.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/19/2026 - 07:10 PM Accepted by SEC EDGAR 08/06/2026 - 08:48 PM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Schmid John P.

(Last) (First) (Middle)

C/O BLOSSOMHILL THERAPEUTICS, INC.

10255 SCIENCE CENTER DRIVE, SUITE 200

(Street)

SAN DIEGO CALIFORNIA 92121-1180

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
08/06/2026

3. Issuer Name and Ticker or Trading Symbol
BlossomHill Therapeutics, Inc. [ BLSM ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Director Stock Option (Right to Buy)	(1)	05/17/2036	Common Stock	67,620	$13.59	D

Explanation of Responses:

1. Immediately Exercisable.

	/s/ Vincent Liptak, Attorney-in-Fact	08/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)